# 2026-09566: DEA Bans Bizarre Chemical: CUMYL-PEGACLONE Joins Schedule I Ranks

2026-09566, Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I, is a Federal Register rule from Justice Department, Drug Enforcement Administration published 2026-05-13, effective 2026-05-13; PRIA reads it as touching household money (as of 2026-06-11).

- Canonical: https://policyrisk.com/federal-register/2026-09566
- As of: 2026-06-11
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-09566
- Title: Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
- Type: Rule
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 91 FR 26913
- Published: 2026-05-13
- Effective: 2026-05-13
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-11

## In one line

DEA Bans Bizarre Chemical: CUMYL-PEGACLONE Joins Schedule I Ranks

## Summary

Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.

## Abstract

With the issuance of this final rule, the Drug Enforcement Administration places 5-pentyl-2-(2-phenylpropan-2-yl)pyrido[4,3- b]indol-1-one (other names: CUMYL-PEGACLONE; SGT-151), including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule I of the Controlled Substances Act. This action is being taken, in part, to enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. This action imposes regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle CUMYL-PEGACLONE.

## Effects PRIA read

- Possession and Sale Now Illegal: cost, high. As of May 13, 2026, CUMYL-PEGACLONE is placed in Schedule I. Retail sales of Schedule I controlled substances to the general public are not allowed, and possession or any handling not authorized by the Controlled Substances Act may lead to administrative, civil, or criminal penalties.
- DEA Registration Required to Handle: cost, medium. If you manufacture, distribute, import, export, research, analyze, or possess CUMYL-PEGACLONE, you must be registered with DEA under 21 U.S.C. 822, 823, 957, and 958 and 21 CFR parts 1301 and 1312. Any person who currently handles CUMYL-PEGACLONE and is not registered may not continue to handle it…
- Temporary Research Continuation Window: benefit, low. If on May 13, 2026 you are already registered to conduct research with another Schedule I substance, you may continue research on CUMYL-PEGACLONE provided you submit a completed application for registration or modification no later than 90 calendar days after May 13, 2026. If DEA serves an order to…
- Surrender or Dispose Stocks if Not Registering: cost, medium. If you are unwilling or unable to obtain a Schedule I registration, you must surrender or transfer all quantities of CUMYL-PEGACLONE to a DEA-registered person before the effective date of this rule (May 13, 2026). Disposal must follow 21 CFR part 1317 and applicable Federal, State, local, and Trib…
- Registration Compliance: Security, Records, Quotas: cost, medium. DEA registrants handling CUMYL-PEGACLONE must follow Schedule I rules for security, employee screening, labeling and packaging, quotas for manufacture, initial and biennial inventories (including an initial inventory on the date the registrant first engages in handling and inventories every two yea…
- DEA Finds No Significant Small-Entity Impact: benefit, low. DEA certified under the Regulatory Flexibility Act that this final rule will not have a significant economic impact on a substantial number of small entities. DEA notes there appear to be no legitimate marketed drug sources and no evidence of significant diversion from legitimate suppliers.

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-22843](https://policyrisk.com/federal-register/2026-22843): Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ep…, 2026-11-10
- [2026-22842](https://policyrisk.com/federal-register/2026-22842): Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sal…, 2026-11-10

## Sources
- [2026-09566 on federalregister.gov](https://www.federalregister.gov/documents/2026/05/13/2026-09566/schedules-of-controlled-substances-placement-of-cumyl-pegaclone-in-schedule-i)
- [2026-09566 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-05-13/pdf/2026-09566.pdf)

## Related
- [Previous: 2026-09565, Modernizing Spectrum Sharing for Satellite Broadband](https://policyrisk.com/federal-register/2026-09565)
- [Next: 2026-09575, Extension of Import Restrictions Imposed on Categories of Archaeological and Et…](https://policyrisk.com/federal-register/2026-09575)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-09566 (as of 2026-06-11).
